Altimmune, Inc. · NASDAQ:ALT
Altimmune — Investor Presentation (May 2025)
39 slides from Altimmune's investor presentation, May 2025
Slide 1: Altimmune Corporate Presentation May 2025
Altimmune Corporate Presentation May 2025
Slide 2: Forward-looking Statements
Forward-looking Statements Safe-Harbor Statement This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements
Slide 3: Pemvidutide Vision: A Transformational Therapy Across Related Diseases
Pemvidutide Vision: A Transformational Therapy Across Related Diseases Designed to cover the spectrum of steatotic liver disease and its primary causes Obesity MASH ALD AUD Ph2b top line Ph2 trial Ph2 trial data Q2 2025 initiation Q3 initiation Q2 2025 2025 $131.9M cash, cash equivalents and short-t
Slide 4: Seasoned Management Team
Seasoned Management Team Vipin K. Garg, PhD Greg Weaver, MBA Scott Harris, MD President & CEO Chief Financial Officer Chief Medical Officer Scot Roberts, PhD Bertrand Georges, PhD Raymond Jordt, MBA Chief Scientific Officer Chief Technology Officer Chief Business Officer 4
Slide 5: Pursuing Multiple Indications with Key Milestones
Pursuing Multiple Indications with Key Milestones PRECLINICAL PHASE 1 PHASE 2 PHASE 3 STATUS / UPCOMING MILESTONES** Obesity Completed successful EOP2 meeting MASH* IMPACT Phase 2b topline data 2Q 25 AUD Phase 2 trial initiation 2Q 25 ALD Phase 2 trial initiation 3Q 25 **expected dates *FDA has gran
Slide 6: Pemvidutide: Novel GLP-1/Glucagon Dual Receptor Agonist
Pemvidutide: Novel GLP-1/Glucagon Dual Receptor Agonist Potential Treatment of Choice for Liver and Cardiometabolic Diseases 1:1 POTENCY OF GLP-1 AND GLUCAGON Compelling clinical data to-date support continued development in multiple indications Direct Appetite effects on Liver Cravings Clinically m
Slide 7: Pemvidutide: Designed to Address Major CV Risk Factors
Pemvidutide: Designed to Address Major CV Risk Factors >15% >75% 15-20% Weight Loss Liver Fat LDL-C Reduction Reduction 7
Slide 8: Managing Comorbidities is Essential to Treating Obesity
Managing Comorbidities is Essential to Treating Obesity Most Significant Comorbidities Relate to Lipid and Liver Fat Disorders 66-70% 58-75% MASLD3,4,5 45-55% Dyslipidemia1,2 15-36% MASH3,4,6 Hypertension1,7 1.Bays, Harold, et. al. (2013) Obesity, adiposity, and dyslipidemia: A consensus statement f
Slide 9: Pemvidutide: MOMENTUM Phase 2 Clinical Data Summary
Pemvidutide: MOMENTUM Phase 2 Clinical Data Summary
Slide 10: Weight Loss of 15.6% Continuing at Week 48 on 2.4 mg
Weight Loss of 15.6% Continuing at Week 48 on 2.4 mg Relative Weight Loss (%) Relative Weight Loss Curves (%) *** p < 0.001 vs. placebo (MMRM) MMRM, mixed model for repeated measures MMRM, mixed model for repeated measures 10
Slide 11: Pemvidutide: Improved Quality of Weight Loss
Pemvidutide: Improved Quality of Weight Loss Class-leading Visceral fat is a CV risk factor Lean Mass Preservation* Preferential Loss of Visceral Fat Study Lean Loss Subcutaneous Fat Visceral Fat Drug Study Duration Ratio LS Mean Change from Baseline (% ± SE) LS Mean Change from Baseline (% ± SE) 0
Slide 12: Enhanced Lipid Reductions in Subjects with Elevated Baseline Levels
Enhanced Lipid Reductions in Subjects with Elevated Baseline Levels Triglycerides Total Cholesterol LDL > 150 mg/dL at Baseline > 200 mg/dL at Baseline > 130 mg/dL at Baseline LS Mean Change from Baseline (% ± SE) 0 0 0 -10 -2.4% -20 -13.1% -4.4% -10 -10 -30 -12.1% -40 -33.1% -20 -36.3% * -50 * -14.
Slide 13: Overview of Adverse Events
Overview of Adverse Events Treatment Characteristic Placebo 1.2 mg 1.8 mg 2.4 mg (N=97) (N=98) (N=99) (N=97) SAEs related to study drug N (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.0%) Drug-related AEs leading to discontinuation N (%) 2 (2.1%) 4 (4.1%) 16 (16.2%) 15 (15.5%) Gastrointestinal (GI) AEs—mainly
Slide 14: Pemvidutide in MASH
Pemvidutide in MASH: Combining direct liver targeting with clinically meaningful weight loss to optimize MASH treatment
Slide 15: The Rising Prevalence of MASH
The Rising Prevalence of MASH Projected MASH Projected MASH US Prevalence by Stage (2030)1 Prevalence in the US (2030)1 30 63% 27.5M F4 F0 increase 3.5M 3.9M 25 Prevalence (M) 20 16.5M F3 4.5M 15 F1 10 9.0M F2 5 6.1M 0 2015 2030 1. Estes C, et. al. Modeling the epidemic of nonalcoholic fatty liver d
Slide 16: Significant Comorbidities Associated with MASH
Significant Comorbidities Associated with MASH Addressing Comorbidities Essential for Comprehensive MASH Treatment1 1 1.Younossi et al. (2016) North America Prevalence. Hepatology 64(1):73 Supplement (http://onlinelibrary.wiley.com/doi/10.1002/hep.28431/suppinfo) 16
Slide 17: Pemvidutide: MASLD Phase 1b Clinical Data Summary
Pemvidutide: MASLD Phase 1b Clinical Data Summary
Slide 18: Pemvidutide: Up to 76.4% Reduction of Liver Fat in Phase 1b MASLD Trial
Pemvidutide: Up to 76.4% Reduction of Liver Fat in Phase 1b MASLD Trial Relative Reduction Responder Analyses at Week 24 (N=56) at Week 24 30% Normalization (N=56) 50% 90 Reduction **** Reduction (≤5% LFC) *** *** 100.0% 75.2% 100 76.4% **** LS Mean Change from Baseline (% ± SE) 92.3% 80 90 **** 84.
Slide 19: Magnitude of Liver Fat Reduction Correlates with MASH Resolution & Fibrosis Improvement
Magnitude of Liver Fat Reduction Correlates with MASH Resolution & Fibrosis Improvement Liver Fat Reduction Drives MASH Improvement19 70 60 50 Pemvidutide >75% Response Rate (%) 40 30 liver fat 20 reduction 10 at week 24 0 MASH Resolution Fibrosis Improvement Liver Fat Reduction > 50% reduction > 30
Slide 20: Class-Leading Liver Fat Reduction among MASH Agents
Class-Leading Liver Fat Reduction among MASH Agents 0.4 mg* 100 mg 4.8 mg 6.0 mg 2.5 mg 1.2 mg 1.8 mg 2.4 mg (Q2W) (QOD) 80 mg 10 mg 15 mg 10 mg 30 mg 44 mg 28 mg 50 mg 10 mg Sema (QW) 1 mg (QD) Pbo Pbo Pbo Pbo Pbo Pbo Pbo Pbo Pemvidutide Efinopegdutide Efruxifermin Survodutide Semaglutide Tirzepati
Slide 21: MASLD Ph1b Best Case Example
MASLD Ph1b Best Case 95% relative reduction in liver fat in a patient with Example: high liver fat (normalization within 24 weeks) Near Complete Baseline Week 24 De-Fatting of 32.3% 1.7% Liver with Pemvidutide PDFF % PEMVIDUTIDE 1.8 mg 21
Slide 22: Pemvidutide: IMPACT Phase 2b MASH Trial
Pemvidutide: IMPACT Phase 2b MASH Trial
Slide 23: IMPACT Phase 2B Biopsy-driven F2/F3 MASH Trial
IMPACT Phase 2B Biopsy-driven F2/F3 MASH Trial Topline Data 2Q 2025 Screening/Randomization 1.2 mg weekly (N~38) 1.8 mg weekly (N~76) Key endpoints Primary MASH resolution or Placebo weekly (N~76) fibrosis improvement Secondary Week 24 Week 48 Weight Loss (WL) Noninvasive tests (NITs) Liver Biopsy/W
Slide 24: IMPACT Phase 2b Trial: Designed for Success
IMPACT Phase 2b Greater Liver Greater Biopsy Trial: Fat Reduction Responses Designed for Success Large Increased Sample Size Study Power Biopsy Re-Reads Minimize and the use the Placebo of 3 Readers Response 24
Slide 25: Pemvidutide has the Potential to be a Complete Solution for MASH
Pemvidutide has the Potential to be Pemvidutide 1:1 GLP-1/Glucagon a Complete GLP-1/GIP Solution for Significant weight loss, Significant weight loss, Weight Loss rapid liver effect MASH modest liver effect THR-β FGF21 Insignificant weight loss, Rapid liver effects, modest liver effect insignificant
Slide 26: Leveraging Pemvidutide's Novel MoA to Open New Opportunities
Leveraging Pemvidutide’s Novel MoA to Open New Opportunities Addressing large, under-served patient populations in AUD and ALD
Slide 27: Pemvidutide: Positioned to Address Significant Unmet Needs in AUD & ALD
Pemvidutide: Pemvidutide Treatment Could Halt Progression of AUD to ALD Positioned to Address Significant 5+/day AUD ALD Unmet Needs Up to 28.1M patients have AUD20 Up to 6.6M patients have ALD21 in AUD & ALD Designed to address alcohol misuse and liver inflammation, with added promise of weight los
Slide 28: AUD: Significant Societal Burden
AUD: Significant Societal 7th Leading cause of Burden death and disability globally due to alcohol1 Alcohol is 3rd leading cause of preventable cancer after tobacco and obesity $249B Total cost of alcohol misuse in the US in 20102 Surgeon General Advisory January 2025 1. 2. GBD 2016 Alcohol Collabor
Slide 29: AUD: One of the Largest Known Healthcare Treatment Gaps
AUD: One of the Largest Known Healthcare Treatment Gaps 1 30 28.1M 25 Prevalence (M) 20 15 10 Only 2.0% of patients drug-treated 5 2.2M 552K 0 AUD Population Treated Drug-treated 1. SAMHSA 2023 NSDUH Survey 29
Slide 30: AUD Patients Typically Have Significant Comorbidities
In addition to managing underlying alcohol misuse, AUD patients with AUD require therapies to address comorbidities Patients Typically Have Cardiometabolic Comorbidities Significant Comorbidities 90% will develop 66% are overweight liver steatosis1 or have obesity2 45% have 23% have hypertension3 hy
Slide 31: Pemvidutide Suppresses Alcohol Intake in Preclinical Model
Pemvidutide Hamster Free-Choice Model Suppresses Alcohol 100 vehicle pemvidutide 10 nmol/kg % Alcohol Intake per Day (Alcohol/Total Volume) Intake in 90 Preclinical 80 Model 70 60 50 40 30 20 10 0 0 2 4 6 8 10 12 14 16 18 20 Day Water and 15% ethanol solution 31
Slide 32: Pemvidutide: Phase 2 AUD Trial Design
Pemvidutide: Phase 2 AUD Trial Design Week 1 Week 24 Screening/Randomization 1.2 mg 1.8 mg 2.4 mg weekly (N~50) 4 Weeks 4 Weeks Key endpoints Primary Change in heavy placebo weekly (N~50) drinking days Secondary Randomized, double-blind, placebo-controlled trial of Change in biomarkers ~ 100 subject
Slide 33: Critical Need for Drugs that Improve Liver Health and Reduce Alcohol Consumption
Critical Need Alcohol Liver Disease for Drugs that Result of chronic, excessive alcohol use Improve Liver Health and Similar to MASH, disease progression begins with liver Reduce steatosis, which may lead to fibrosis, and ultimately cirrhosis Alcohol Consumption Up to 6.6 million Americans affected
Slide 34: Obesity Significantly Increases Risk of Poor Alcohol-Related Liver Outcomes
Obesity Obesity Potentiates Alcohol-Related Liver Mortality 1 Significantly Increases 20 Baseline Risk 17.3 Risk of Poor 18 Excess Obesity Risk 16 Alcohol- 14 Excess Alcohol Risk Excess Interaction Risk Related Liver Relative Risk 12 Outcomes 10 10 For heavy drinkers, 8 increasing BMI increases 6 al
Slide 35: Pemvidutide: Phase 2 ALD Trial Design
Pemvidutide: Phase 2 ALD Trial Design Randomized, double-blind, placebo-controlled trial of ~ 100 subjects with obesity and ALD Screening/Randomization 1.2 mg 1.8 mg 2.4 mg weekly (N~50) 4 Weeks 4 Weeks Key eligibility placebo weekly (N~50) • Liver Stiffness Week 24 Week 48 Measurement (LSM) (10 to
Slide 36: Catalysts
Clinical and Regulatory Milestones & Near-Term Catalysts 2024 2025 2026 NOV Q1 Q2 Q2 Q3 Q4 Q1 Successful INDs in Initiate IMPACT Initiate FDA EOP2 Initiate FDA EOP2 AUD and Phase 2 Phase 2b Phase 2 meeting for MASH meeting for ALD AUD trial 24-week ALD trial MASH Phase 3 obesity Cleared topline data
Slide 37: Pemvidutide Vision: Transformational Therapy Across Multiple Indications
Pemvidutide Vision: Transformational Therapy Across Multiple Indications OBESITY MASH AUD ALD Treating the A Complete Major Cause of No Approved Comorbidities Solution Liver Damage Therapies 37
Slide 38: Thank You
Thank You )altimmune
Slide 39: Appendix
Appendix Slide 30 Data Sources: • Pemvidutide: Phase 1b NAFLD Study Topline Results Extension • Efinopegdutide: EASL Congress 2023, Manuel Romero-Gomez Presentation • Efruxifermin: Harrison et al. “Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMO